Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1954 | Bleomycin | Radiation | Misc | 0.043847 | -0.0884 | 0.6166 | 0.2476 | 0.7506 | 0.05535 | 0.98102 |
HCC1954 | Ipatasertib | AKT | PI3K/mTOR | 1.4342 | 0.2509 | 0.2145 | 0.0288 | 0.9249 | 0.80694 | 0.98539 |
HCC1954 | Alpelisib | PI3Ka | PI3K/mTOR | 1.2292 | -0.3408 | 0.2652 | 0.1073 | 0.8509 | 4.4679 | 0.99224 |
HCC1954 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0070107 | -0.3632 | 0.9490 | 0.3748 | 1.0954 | 0.010784 | 0.99379 |
HCC1954 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9607 | -0.0374 | -0.0050 | 0.0000 | Inf | -1.0282 |
HCC1954 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0096629 | -0.3280 | 0.5536 | 0.1704 | 0.7380 | 0.018218 | 0.98125 |
HCC1954 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.3263 | 0.6531 | 0.1358 | 0.0000 | Inf | 0.52018 |
HCC1954 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.014251 | -0.0830 | 0.5651 | 0.1455 | 1.3479 | 0.013876 | 0.98856 |
HCC1954 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.8349 | -0.0093 | -0.0064 | 1.3800 | 7.2097 | 0.65841 |
HCC1954 | Buparlisib | pan PI3K | PI3K/mTOR | 0.52073 | -0.4576 | 0.4002 | 0.1883 | 1.6194 | 0.7982 | 0.9975 |
HCC1954 | Pictilisib | pan PI3K | PI3K/mTOR | 0.94449 | -0.2272 | 0.3087 | 0.1077 | 0.8502 | 2.3595 | 0.9976 |
HCC1954 | Ceritinib | ALK | RTK | 2.3105 | -0.4446 | 0.1668 | 0.0701 | 2.4217 | 3.1138 | 0.99363 |
HCC1954 | Neratinib | EGFR/HER2 | RTK | 0.067164 | -0.0909 | 0.4293 | 0.1185 | 0.6344 | 0.096489 | 0.97441 |
HCC1954 | Tivantinib | MET | RTK | 0.16715 | -0.3846 | 0.5511 | 0.2533 | 1.4818 | 0.24265 | 0.99675 |
HCC1954 | Cediranib | VEGFR/cKIT | RTK | 4.092 | -0.3202 | 0.0756 | 0.0534 | 4.9589 | 4.5507 | 0.99308 |
HCC1954 | Cabozantinib | VEGFR2/MET | RTK | 10.9106 | 0.6390 | -0.0135 | -0.0074 | 5.0000 | 13.0234 | 0.87916 |
CAL-120 | Abemaciclib | CDK4/6 | Cell cycle | 0.247 | -0.1408 | 0.4780 | 0.0849 | 0.3730 | 4.696 | 0.95026 |
CAL-120 | Palbociclib | CDK4/6 | Cell cycle | Inf | 0.6687 | 0.1422 | 0.0012 | 1.4451 | 0.023318 | 0.96675 |
CAL-120 | AZD7762 | CHK1/2 | Cell cycle | 0.15216 | -0.4949 | 0.5265 | 0.2150 | 1.1035 | 0.26511 | 0.97495 |
CAL-120 | Volasertib | PLK | Cell cycle | 0.0018536 | 0.0258 | 0.6758 | 0.2649 | 2.5191 | 0.001844 | 0.99276 |
CAL-120 | Dinaciclib | pan CDK | Cell cycle | 0.009892 | -0.1320 | 0.5549 | 0.1203 | 4.4157 | 0.010404 | 0.99947 |
CAL-120 | Cisplatin | Chemo | Chemotherapy | 2.9328 | 0.1876 | 0.1824 | 0.0229 | 0.9231 | 4.0426 | 0.98856 |
CAL-120 | Doxorubicin | Chemo | Chemotherapy | 0.009438 | -0.2475 | 0.6969 | 0.1356 | 1.3775 | 0.011488 | 0.99278 |
CAL-120 | Taxol | Chemo | Chemotherapy | 0.0028769 | -0.1987 | 0.7463 | 0.3104 | 2.6390 | 0.0032354 | 0.97877 |
CAL-120 | Topotecan | Topo I | Chemotherapy | 0.007493 | -0.3364 | 0.9130 | 0.2556 | 1.1649 | 0.010414 | 0.97973 |